BioCentury
ARTICLE | Clinical News

Agios discontinues PKD candidate

December 16, 2016 12:01 AM UTC

Agios Pharmaceuticals Inc. (NASDAQ:AGIO) fell $10.66 (19%) to $45.28 in early after hours trading after it said it discontinued development of AG-519 to treat pyruvate kinase deficiency after FDA placed a clinical hold on the candidate. On a conference call Thursday, CEO David Schenkein said the hold was linked to a drug-related case of cholestatic hepatitis in a healthy volunteer in a Phase I study. Agios said last week it was investigating the case (see BioCentury Extra, Dec. 5).

Agios had previously reported a case of grade 2 thrombocytopenia from the trial (see BioCentury Extra, June 9)...

BCIQ Company Profiles

Agios Pharmaceuticals Inc.